AS A TOOL FOR DEVELOPMENT

SUJITA MISHRAPI/289

IPR

2

Table of contents

Introduction

National Development Goals

1st,2nd,3rd,stage of IP development

Success story of BIOCON,NIRMA,and,PLIVA

Conclusion

3

Introduction

4

Introduction

5

QUESTIONS TO CONSIDER

What is ‘development’?

Is IP a tool for development?

How can IP address development goals?

Is IP solution of our problems?

Introduction

6

Examples of National Development Goals

SECURITY

EFFECTIVE GOVERNANCE

SUSTAINABLE ENVIRONMENT

ECONOMIC

SOCIAL

7

How Can IP Address Development Goals?Each stage in the development of Intellectual Property

“a development tool ladder” can contribute towards meeting the goals of economic and social advancement.

1st Stage of IP Development

2nd Stage of IP Development

3rd Stage of IP Development

8

1st Stage of IP Development

Conception and expression of ideas,experimenting in innovation.

Allows for self-expression and building of esteem,talent and unique identity.

Individual and National level.

Results in vibrant culture, progressive society.

9

Examples of Technological Advancements :-

APPLE iPhone (allows video play back, games, email, web access, camera and non game applications)

iPod,and

iTunes

1st Stage of IP Development

10

2nd Stage of IP development

IP product/ process applied in the various domains of human activity and enhance daily life.

Examples :-

Education – digital white boards, literary and cultural books.

Health – new procedures.

Government and Business: e-commerce, e -banking, e-voting.

Technology: used in law enforcement - Wireless Crime Fighting Measures,etc.

Employing Eco-efficient approaches to industry and manufacturing.

11

3rd Stage of IP Development

Economic exploitation of IP.

Provides business opportunities for micro to large business.

Proper marketing of products and services are crucial to the success or failure of a product/process and its parent company.

12

Impact of Intellectual property on SMEs

The impacts of IP will be on SMEs in three ways and the sheer survival of SMEs will depend on Tripod of :-

Cost Quality Delivery

13

The Challenges for SMEs

1. Achieve Cost Efficiency.

2. Produce quality comparable to the best.

3. Efficient delivery of the "goods & services"; to the consumer.

4. Become world class, this does not necessarily mean world scale. 

14

Enhancing Competitiveness of SMEs through Innovation

Creating new products or services.

Re-engineering products or services.

New processes to improve productivity.

Developing new maketing techniques to expand sales.

New forms of management systems and techniques to improve operational efficiency

15

IP as a Valuable Asset

IP is now recognized as one of the most valuable assets in business transactions in the form of ;

Licensing Agreements – patents, copyright, trade marks.

Manufacturing.

Purchase or Distribution Agreements.

Mergers or acquisitions.

16

17

Founded as an brewing enzyme extraction company 1978.

Next in 1984 tried to get an alternative to ‘Koji enzymes’.

In 1989, acquired by Unilever.

By 1990’s Koji enzymes were a success, and got an added advantage in fermentation drugs.

Now produces everything from insulin to antibodies.

Has been leading the biotech industry for 20+ years.

Success story of BIOCON

18

Biocon's initial operation was to extract an enzyme from papaya. Under Kiran Mazumdar Shaw's stewardship Biocon transformed from an industrial enzymes company to an integrated biopharmaceutical company with strategic research initiatives. Today Biocon is recognized as India's pioneering biotech enterprise.

BIOCON INDIA:

Biocon was founded on November 29, 1978 as a joint venture between Biocon Biochemicals Ltd. of Ireland and an Indian entrepreneur, Kiran Mazumdar Shaw.

In 1979, Biocon became the first Indian company to manufacture and export enzymes to USA and Europe. Unilever plc. acquired Biocon Biochemicals Ltd.

In 1989, Biocon became the first Indian biotech company to receive US funding for proprietary technologies.

Success Story of BIOCON

19

Problems faced

Not being considered creditworthy, being

turned down by banks

Difficulty getting skilled people,

difficulty being a woman entrepreneur

when dealing with vendors

Solutions

Used her own contacts at Canara bank and

finances at the outset

Bought along male personnel in price

negotiations, Biocon was started in a garage

Problems and Solutions of BIOCON

20

Products of BIOCON

21

INTRODUCTION:-Founder of Nirma is Dr. Karsanbhai Patel.

In the early 1970s, when Nirma washing powder was introduced in the low-income market.

Starting as a one-product one-man outfit in 1969, Nirma became a Rs 17 billion company within three decades.

The brand name became almost synonymous with low-priced detergents and toilet soaps.

In 2000, Nirma had a 15% share in the toilet soap segment and more than 30% share in the detergent market.

Success Story of NIRMA

22

Nirma Ltd:-

Nirma is one of the most recognizable Indian brands.

Nirma has about 14, 000 employee-base and annual turnover of more than Rs. 25,000 crores.

Nirma rewrote the marking rules and its success story became one of the widely discussed case studies in the B-schools across the world.

Today Nirma has one of the largest volume sales with a single brand name in the world.

In 2004, Nirma's annual sales touched 800,000 tones.

Success Story of NIRMA

23

Industrial salt

Glycerin

Sulfuric acid

Soda ash

Soaps

Detergents

Major plants of NIRMA

24

Lowest Cost system in India.

Speed in distribution.

Flexibility.

Wider reach.

Speedy market intelligence.

Competitive edge & better focus.

Eco-freindly and environmentally safe.

Success Story of NIRMA

25

Pliva operates in over 30 countries worldwide and is the leading pharmaceutical company based in Central and Eastern Europe. It specializes in the development, production and distribution of generic pharmaceutical products, including biologicals, and other generics, as well as active pharmaceutical ingredients.

A team of Pliva's researchers, Gabrijela Kobrehel et.al. led by Dr. Slobodan Đokić, discovered Azithromycin in 1980. Azithromycin is marketed in Eastern Europe under the name Sumamed and was licensed to Pfizer, who market it in Western Europe and the USA under the name Zithromax, where it is one of the top-selling antibiotics. Royalties from Pfizer provided PLIVA's main income stream until the expiry of the Azithromycin patent in 2005.

Success story of PLIVA

26

Goodwill of Brands

27

Conclusion

IP is good for economic

development.IP is solution

of our problem.

IP creates competitionin market.

28